Core Insights - Esperion announced two post-hoc analyses from the CLEAR Outcomes trial, demonstrating a 22% reduced risk of ischemic stroke for patients taking bempedoic acid compared to placebo [1][5] - The analyses also indicated that bempedoic acid reduced major adverse cardiovascular events (MACE) in high-risk patients with autoimmune or inflammatory diseases similarly to those without such conditions [1][5] Group 1: Clinical Findings - Bempedoic acid reduced the risk of ischemic stroke by 22% compared to placebo, with 90% of the 293 strokes recorded being ischemic [5] - Approximately 10% of the 13,970 participants in the CLEAR Outcomes trial had prior autoimmune and inflammatory diseases, which increase the risk of MACE [5] - Patients with autoimmune or inflammatory diseases experienced similar clinical benefits from bempedoic acid as those without these conditions [5] Group 2: Expert Commentary - Dr. Luke Laffin emphasized the elevated cardiovascular burden faced by patients with autoimmune and inflammatory diseases, highlighting the meaningful reductions in cardiovascular events provided by bempedoic acid [2] - Sheldon Koenig, President and CEO of Esperion, noted that the findings strengthen the evidence base for NEXLETOL as a therapy for cardiovascular risk reduction, particularly for statin-intolerant patients [2] Group 3: Product Indications - NEXLIZET and NEXLETOL are indicated to reduce the risk of major adverse cardiovascular events in adults at increased risk who cannot take statin therapy [5][6] - Bempedoic acid is part of these therapies aimed at lowering LDL-C levels in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH) [5][6]

Core Insights - VEON Ltd. announced that its subsidiary JazzCash has onboarded its 1 millionth Raast QR-enabled merchant, marking a significant milestone in Pakistan's transition to a cashless economy [1][3] Group 1: Digital Payment Infrastructure - Raast is Pakistan's national instant payment system launched by the State Bank of Pakistan in 2021, enabling interoperability across the financial sector and promoting digital payment tools [2] - JazzCash has established the largest digital payment acceptance network in Pakistan, facilitating digital transactions for various types of businesses, including corner shops and online retailers [3] Group 2: Economic Impact - JazzCash serves a registered customer base of 58 million and processed over PKR 15 trillion (approximately USD 53 billion) in transaction value in 2025, representing about 13% of Pakistan's GDP [8] - The onboarding of 1 million QR-enabled merchants is seen as a crucial step in integrating digital payments into the daily lives of Pakistanis, supporting small businesses and enhancing the digital economy [7] Group 3: Leadership and Vision - Kaan Terzioglu, CEO of VEON, commended the efforts of the Prime Minister and the State Bank of Pakistan in promoting digital payments and financial inclusion, emphasizing the importance of a cashless economy for national growth [6] - Murtaza Ali, CEO of JazzCash, highlighted the focus on making financial services accessible and relevant for all Pakistanis, reinforcing the commitment to support small businesses and women-led enterprises [7] Group 4: Company Overview - VEON is a digital operator providing connectivity and digital services to nearly 150 million users across five countries, aiming to transform lives through technology-driven services [11] - JazzCash operates under a Branchless Banking charter, offering a wide range of services including payments, lending, and government-to-person payments, thereby enhancing financial inclusion in Pakistan [12]

Core Insights - Pacira BioSciences announced findings from two real-world studies demonstrating the economic benefits of EXPAREL in total knee arthroplasty (TKA) and spinal fusion, showing lower total costs of care compared to traditional analgesics [1][2] Study Findings - The studies included propensity score-matched cohorts evaluating outcomes on surgery day and through 30 days of follow-up in commercial and Medicare Advantage populations, revealing lower total costs and reduced healthcare resource utilization with EXPAREL [2] - In the spinal fusion study, the reductions in costs were primarily attributed to a shorter length of hospital stay for patients treated with EXPAREL [2] Specific Results from TKA Study - In the TKA study, EXPAREL was associated with significantly lower total costs compared to ropivacaine, with reductions of $409 in the commercial cohort and $1,359 in the Medicare Advantage cohort, both with P<0.001 [3] - The index procedure costs were also lower for EXPAREL, with reductions of $328 and $781 for commercial and Medicare Advantage cohorts respectively, both with P<0.0001 [3] - Additional findings included reduced home health utilization and lower inpatient admissions in the commercial population, with P<0.05 for all [3] Specific Results from Spinal Fusion Study - In the spinal fusion study, patients treated with EXPAREL had significantly lower mean total costs of $5,993.17 compared to non-LB analgesia, with P<0.05 [4] - The reduction in total medical costs was $6,001.19, also with P<0.05, and there were decreases in outpatient costs [4] - Patients treated with EXPAREL experienced a shorter length of stay by 1.83 days, with P<0.0001, and no differences in emergency department visits or inpatient readmissions [5] Company Commitment - Pacira is dedicated to advancing the economic understanding of postsurgical pain management through real-world evidence, emphasizing the value of non-opioid approaches like EXPAREL [3] - The findings support the role of EXPAREL in multimodal pain management strategies, aiming to improve patient outcomes and reduce economic barriers to access [3] Upcoming Presentations - Pacira will present these findings at the Orthopaedic Research Society (ORS) 2026 Annual Meeting, highlighting the economic advantages of EXPAREL in orthopedic procedures [1][3]

Core Viewpoint - American Fusion Inc. has successfully obtained a default judgment to cancel 1,683,000,000 improperly issued shares, restoring the integrity of its capitalization structure and preparing for its inaugural quarterly filing as a fully reporting company [1][2]. Group 1: Share Cancellation and Corporate Actions - The court ordered the cancellation of 1.683 billion shares that were improperly issued, confirming that the underlying transactions were never consummated [1][5]. - The cancellation is expected to be reflected in the Company's records before the end of the current quarter, ensuring accurate reporting of issued and outstanding shares [5]. - The completion of this share cancellation is part of a series of corporate governance and regulatory milestones aimed at establishing a transparent public company platform [3]. Group 2: Strategic Priorities and Future Plans - Following the completion of the share cancellation, the Company is focused on pursuing a listing on a national securities exchange and advancing the commercialization of Kepler Fusion Technologies' Texatron aneutronic fusion platform [3]. - The Company has completed a two-year PCAOB audit, establishing a foundation for financial reporting and regulatory compliance [5]. - The Company has filed a Form 10 registration statement with the SEC, which is expected to become effective automatically 60 days after filing [5]. Group 3: Corporate Identity and Structure - The Company has changed its name to American Fusion Inc. and its trading symbol to AMFN, aligning its public identity with its strategic direction following the merger with Kepler Fusion Technologies [5]. - The business combination with Kepler Fusion Technologies was completed on February 27, 2026, and the Company is finalizing purchase price accounting and related valuation analysis [5]. Group 4: Related Legal Matters - In related litigation, the Delaware Court of Chancery denied motions for expedited proceedings regarding corporate control claims, determining that the plaintiff failed to establish a valid claim [6]. - The Company intends to file a motion to dismiss in response to the ongoing legal matters [7].

Core Insights - Vor Bio has initiated the first patient dosing in the Phase 3 UPSTREAM SjD trial for telitacicept, targeting primary Sjögren's disease, which currently lacks approved therapies [1][2] Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [1] - The company is advancing global development programs for major autoimmune indications, including a Phase 3 trial for generalized myasthenia gravis (gMG) and primary Sjögren's disease (SjD) [7] Product Information - Telitacicept is a novel investigational recombinant fusion protein that inhibits BAFF and APRIL, two cytokines crucial for B cell survival, thereby reducing autoreactive B cells and autoantibody production [5] - Telitacicept is already approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG), with additional regulatory filings for SjD and IgA nephropathy (IgAN) underway [6] Clinical Trial Details - The UPSTREAM SjD trial will involve approximately 250 adult patients with active primary Sjögren's disease, evaluating the efficacy and safety of telitacicept compared to placebo [2] - The primary endpoint is the change in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48, with key secondary endpoints assessing systemic disease activity, glandular function, and patient-reported symptoms [2] Disease Context - Sjögren's disease is a chronic autoimmune condition characterized by overactive B cells leading to inflammation and damage to moisture-producing glands, with symptoms including dry eyes, dry mouth, fatigue, and systemic complications [3][4] - The disease is underdiagnosed, with about half of the cases unrecognized, and predominantly affects women [4]

Core Insights - JE Cleantech Holdings Ltd has secured new orders worth approximately USD 12 million for precision cleaning systems in Q1 2026, with deliveries expected over the next 12 months [1] Group Overview - JE Cleantech Holdings is based in Singapore and primarily engaged in the sale of precision cleaning systems and centralized dishwashing services [4] - The company designs, develops, manufactures, and sells cleaning systems for various industrial applications, focusing on precision cleaning with advanced features [4] Strategic Focus - The company aims to accelerate growth by expanding its product portfolio, enhancing engineering and R&D capabilities, and capturing opportunities in emerging industries while aligning with sustainability goals [3] - JE Cleantech seeks to solidify its position as a leading provider of industrial precision cleaning solutions and a preferred partner for customers with complex requirements [3][2]

Core Insights - Evaxion A/S, a clinical-stage TechBio company, has developed novel vaccine design concepts for polio in collaboration with the Gates Foundation, utilizing its AI-Immunology™ platform [1][7] - The new polio vaccine concepts aim to combine the strengths of existing vaccines, addressing their shortcomings and enhancing the potential for polio eradication [2][3] - Evaxion will present these concepts at the World Vaccine Congress in Washington D.C. from March 31 to April 2, 2026 [1][6] Vaccine Development - Current polio vaccines are based on inactivated or attenuated virus versions, which have limitations in certain settings [2] - The AI-Immunology™ platform has enabled the development of hybrid capsid designs and de novo B-cell antigen approaches for the new polio vaccine [7][8] - Initial results from the new vaccine concepts support further development and potential collaboration opportunities [4] Additional Programs - Evaxion will also present data from its EVX-V1 program targeting Cytomegalovirus (CMV), which combines novel AI-discovered antigens with optimized versions of established CMV vaccine antigens [5][7] - The multi-targeted strategy of EVX-V1 is expected to enhance the protective potential of the future vaccine [5] Presentation Details - The presentation on the novel poliovirus vaccine will take place on April 1, 2026, at 16:40 ET, and will be led by Thomas Trolle, PhD [6] - An abstract on AI-powered target discovery for the CMV vaccine will be presented on April 2, 2026, at 10:25 ET by Pär Comstedt [6]

Core Insights - Air Canada CEO Michael Rousseau will retire by the end of Q3 2026 after nearly two decades of leadership, during which he has significantly contributed to the airline's position in the industry [1][3] - The Board of Directors has been focused on CEO succession planning for over two years, including an internal development program and an external search for candidates [2] Group 1: Leadership Transition - The Board has initiated a comprehensive internal development program for high-potential executives and started an external search for additional candidates in January 2026 [2] - Performance criteria for assessing candidates will include the ability to communicate in French, reflecting the company's commitment to its Canadian roots [2] - Rousseau will remain available to ensure a smooth transition during this period [2][4] Group 2: Contributions and Achievements - Rousseau's leadership has been pivotal in navigating challenges such as the 2007-2008 financial crisis and the COVID-19 pandemic, as well as in strategic initiatives like the acquisition of Aeroplan [3] - His tenure is marked by a legacy of financial strength and a focus on customer centricity and employee well-being [3] - The upcoming annual general meeting (AGM) will further recognize Rousseau's contributions to the company [3] Group 3: Company Overview - Air Canada is the largest airline in Canada and a founding member of Star Alliance, serving over 180 airports globally [6] - The Aeroplan program is Canada's premier travel loyalty program with over 10 million members [6] - Air Canada aims for net-zero greenhouse gas emissions by 2050 as part of its climate-related ambitions [6]

Group 1 - Plains All American Pipeline and Plains GP Holdings are progressing with the divestiture of their Canadian NGL business to Keyera Corp, expecting to close the transaction in May 2026 [1][2] - The companies are actively engaged in regulatory processes and integration planning to ensure a smooth transition post-closing [2] - Upon completion of the NGL divestiture, Plains will become a pure play crude oil midstream company with integrated assets from Canada to the U.S. Gulf Coast [2] Group 2 - Plains All American Pipeline operates an extensive midstream energy infrastructure, handling approximately nine million barrels per day of crude oil and NGL [4] - The company provides logistics services and owns a network of pipeline gathering and transportation systems, along with storage and processing facilities [4] - Plains GP Holdings holds a controlling general partner interest in Plains All American Pipeline, making it one of the largest energy infrastructure and logistics companies in North America [5]

Core Insights - SEALSQ Corp has joined the ECHONET Consortium to enhance the security framework of smart home and energy management systems through its INeS PKI platform [3][4][10] Industry Overview - The global smart home market is projected to grow from $127.8 billion in 2024 to $537.3 billion by 2030, at a CAGR of 27.0%, with security and access control being the largest product category [5] - The global IoT security market is forecast to reach $141.8 billion by 2030 at a CAGR of 26.8%, driven by regulations like Japan's JC-STAR cybersecurity framework and the EU Cyber Resilience Act [5] Company Positioning - SEALSQ aims to strengthen its position in the smart home and smart energy IoT fields by providing PKI services that ensure secure device onboarding and compliance for ECHONET Lite devices [6][8] - The company is also a member of the Wi-SUN Alliance, delivering certified PKI services for smart grid and smart city applications, further enhancing its credibility in the sector [7] Technological Contributions - The INeS platform supports secure device onboarding, certificate lifecycle management, and cryptographic trust, tailored for large-scale IoT and embedded environments [4][9] - By integrating PKI into the ECHONET Lite protocol, SEALSQ contributes to stronger compliance with evolving cybersecurity requirements in Japan [8][10] Strategic Importance - The collaboration with the ECHONET Consortium positions SEALSQ at the intersection of high-growth sectors, offering significant commercial opportunities for standards-compliant PKI services across millions of connected devices [5][6]